Endometriosis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. The predisposing factors uterine abnormalities, History of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 6, 1, 17, 7 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Endometriosis - Overview 7
Endometriosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Endometriosis - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Endometriosis - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Addex Therapeutics Ltd 28
APAvadis Biotechnologies Srl 28
Astellas Pharma Inc 29
Bayer AG 29
Dongkook Pharmaceutical Co Ltd 30
ElexoPharm GmbH 30
EndoCeutics Inc 31
Enteris BioPharma Inc 31
Evotec AG 32
Forendo Pharma Ltd 32
Kissei Pharmaceutical Co Ltd 33
Lipicard Technologies Ltd 33
Luye Pharma Group Ltd 34
Nippon Shinyaku Co Ltd 34
Ogeda SA 35
Orphagen Pharmaceuticals Inc 35
Philogen SpA 36
Repros Therapeutics Inc 36
SK Chemicals Co Ltd 37
Takeda Pharmaceutical Company Ltd 37
ValiRx Plc 38
Viramal Ltd 38
Endometriosis - Drug Profiles 39
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 39
ADX-68692 - Drug Profile 40
ASP-1707 - Drug Profile 41
BAY-1128688 - Drug Profile 42
BAY-1158061 - Drug Profile 43
danazol - Drug Profile 44
Drug 1 for Endometriosis - Drug Profile 45
Drug 2 for Endometriosis - Drug Profile 46
Drug 3 for Endometriosis - Drug Profile 47
Drug 4 for Endometriosis - Drug Profile 48
Drug 5 for Endometriosis - Drug Profile 49
Drug to Antagonize P2X3 for Endometriosis - Drug Profile 50
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 51
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 52
EC-313 - Drug Profile 53
elagolix sodium - Drug Profile 54
EVE-104 - Drug Profile 59
fezolinetant - Drug Profile 60
FP-5677 - Drug Profile 63
goserelin biosimilar - Drug Profile 64
goserelin ER - Drug Profile 65
KLH-2109 - Drug Profile 66
leuprolide acetate - Drug Profile 68
LT-6121 - Drug Profile 69
MIA-602 - Drug Profile 70
NHP-07 - Drug Profile 71
NS-580 - Drug Profile 72
Peptides for Endometriosis and Hepatic Tumor - Drug Profile 73
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 74
PGL-2001 - Drug Profile 75
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 76
relugolix - Drug Profile 77
SKI-2670 - Drug Profile 80
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 81
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 82
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 83
Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology - Drug Profile 84
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 85
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 86
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 87
Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile 88
SR-16234 - Drug Profile 89
Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile 90
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 91
telapristone acetate - Drug Profile 92
Tetravil - Drug Profile 101
TOT-206 - Drug Profile 103
triptorelin acetate ER - Drug Profile 104
triptorelin biosimilar - Drug Profile 105
VAL-301 - Drug Profile 106
vilaprisan - Drug Profile 107
VPE-001 - Drug Profile 108
VPEA-004 - Drug Profile 109
Endometriosis - Dormant Projects 110
Endometriosis - Discontinued Products 112
Endometriosis - Product Development Milestones 113
Featured News & Press Releases 113
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Endometriosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Endometriosis - Pipeline by AbbVie Inc, H1 2017
Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2017
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2017
Endometriosis - Pipeline by Astellas Pharma Inc, H1 2017
Endometriosis - Pipeline by Bayer AG, H1 2017
Endometriosis - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
Endometriosis - Pipeline by ElexoPharm GmbH, H1 2017
Endometriosis - Pipeline by EndoCeutics Inc, H1 2017
Endometriosis - Pipeline by Enteris BioPharma Inc, H1 2017
Endometriosis - Pipeline by Evotec AG, H1 2017
Endometriosis - Pipeline by Forendo Pharma Ltd, H1 2017
Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Endometriosis - Pipeline by Lipicard Technologies Ltd, H1 2017
Endometriosis - Pipeline by Luye Pharma Group Ltd, H1 2017
Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Endometriosis - Pipeline by Ogeda SA, H1 2017
Endometriosis - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
Endometriosis - Pipeline by Philogen SpA, H1 2017
Endometriosis - Pipeline by Repros Therapeutics Inc, H1 2017
Endometriosis - Pipeline by SK Chemicals Co Ltd, H1 2017
Endometriosis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Endometriosis - Pipeline by ValiRx Plc, H1 2017
Endometriosis - Pipeline by Viramal Ltd, H1 2017
Endometriosis - Dormant Projects, H1 2017
Endometriosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Endometriosis - Discontinued Products, H1 2017